A new simulation module expands ROP education from diagnosis to hands-on laser therapy.
Haag-Streit (Bern, Switzerland) has taken another step forward in virtual ophthalmic training with the release of an Eyesi laser simulation module, officially debuting at the World ROP Congress 2025 in Florence. After offering a sneak peak during ESCRS 2025, the company is now rolling out the full module to clinicians, trainees and educators focused on advancing retinopathy of prematurity (ROP) management.
The launch adds an interventional layer to the existing Eyesi Indirect ROP Simulator, transforming it from a purely diagnostic platform into a system that now supports therapeutic education as well. With laser therapy still the most widely used treatment for severe ROP, Haag-Streit’s expanded offering aims to close longstanding gaps in experience and access to structured, hands-on training.
From identifying the disease to applying treatment
The original Eyesi Indirect ROP Simulator was designed to reinforce ROP classification and screening. With the new laser module, trainees can move through a more complete workflow that mirrors real-life practice: diagnosing, classifying and treating.
The module focuses specifically on peripheral laser photocoagulation, an established technique that suppresses abnormal vascular activity by placing controlled laser burns in targeted retinal zones. As with screening, laser therapy requires refined motor skills, a detailed understanding of ocular anatomy and comfort operating under indirect visualization. These are competencies that typically take time and repeated exposure to develop, which can be difficult in clinical settings where case volumes or teaching opportunities vary.
READ MORE: Belite Bio’s Tinlarebant Delivers Positive Phase III Results for Stargardt Disease
Surpassing obstacles to learning laser treatments
ROP laser therapy involves a complex interplay of tasks, including maintaining alignment of the viewing system, stabilizing instruments, and keeping the laser spot in focus as it travels across the peripheral retina. Reliable access to hands-on experience is not always guaranteed, especially when dependent on case availability or instructor schedules.
The Eyesi Laser Simulation Module offers a controlled environment where these steps can be rehearsed repeatedly. Simulated setup mirrors the technical demands of the actual procedure, allowing trainees to practice alignment, motion control and laser delivery under indirect visualization without the constraints of clinic time.
READ MORE: Photovoltaic Retina Implant Offers “New Light” for Vision in GA Patients
Realistic laser setup and performance feedback
The module enables users to practice core treatment elements, including “firing” the laser, adjusting power and pulse duration, and managing spacing according to predefined parameters. Training begins with exercises centered on beam control before progressing to peripheral applications, parameter adjustments and pulsed-mode delivery.
Laser spot spacing receives particular emphasis. Burns that are placed too close may lead to excessive tissue interaction, while spacing that is too wide can leave areas untreated and vulnerable to continued VEGF activity.
At the end of each session, trainees receive automated performance feedback. The system tracks total energy delivered, number of burns applied and the extent of treatment area coverage, allowing users to review their performance and monitor improvements over time.
The takeaway
By introducing the Eyesi Laser Simulation Module, Haag-Streit extends its ROP training system into a more comprehensive diagnostic-and-interventional platform. The new module integrates structured laser exercises, adjustable settings, burn-placement practice and objective feedback, creating a cohesive space for honing the technical aspects of peripheral photocoagulation for ROP. In short, it’s another step toward making high-stakes skills feel just a little more teachable.
Editor’s Note: This content is intended exclusively for healthcare professionals. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.